On 12 Nov 2026 Charles River Laboratories closed at $340.81, +70.8% this year; market cap $16.56bn, P/E 412.0.
Health Care · Life Sciences Tools & Services · NYSE · United States
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| Market cap | $16.56bn |
| P/E (trailing) | 412.0 |
| EPS (TTM) | $0.83 |
| Beta | 1.34 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 4 Nov 2026 |
| Next earnings | 3 Feb 2027 |
| YTD | +70.8% |
| 1Y | +98.7% |
| 3Y | +26.1% |
| 5Y | -2.5% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $4.02bn | $-144.34m | $518.49m |
| 2024 | $4.05bn | $10.30m | $501.61m |
| 2023 | $4.13bn | $474.62m | $365.37m |
| 2022 | $3.98bn | $486.23m | $294.91m |
| 2021 | $3.54bn | $390.98m | $532.03m |
We publish no single base value for Charles River Laboratories. Our valuation methods put it between $87.11 and $139.82 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.